cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Acorda Therapeutics Inc
42 own
40 watching
Current Price
$13.05
$-0.45
(-3.33%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
18.38M
52-Week High
52-Week High
24.19600
52-Week Low
52-Week Low
8.97800
Average Volume
Average Volume
0M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
3.3095
iconMarket Capitalization18.38M
icon52-Week High24.19600
icon52-Week Low8.97800
iconAverage Volume0M
iconDividend Yield--
iconP/E Ratio3.3095
What does the Acorda Therapeutics Inc do?
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinson's disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinson's disease; SYN120, which is in Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Read More
How much money does Acorda Therapeutics Inc make?
News & Events about Acorda Therapeutics Inc.
Business Wire
8 months ago
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has received notification from the Nasdaq Stock Market informing the Company that as of June 20, 2023 it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1). Acorda is now in...
Business Wire
9 months ago
Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction with its first quarter 2023 update and financial results on Thursday, May 11 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link...
Business Wire
11 months ago
Acorda Therapeutics, Inc. (Nasdaq: ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Tuesday, April 4 at 1:00pm ET, 10:00am PT. Dr. Cohen will present an overview of the Company and review its 2022 financial and business performance. Participants will be able to submit...
Business Wire
1 year ago
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has revised and updated the long-term financial guidance most recently included in its November 1, 2022 press release announcing its financial results for the third quarter of 2022. The revised guidance corrects certain errors...
Business Wire
1 year ago
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Companys stockholders approved the Reverse Stock Split proposal at its reconvened Special Meeting of Stockholders. We are grateful to our shareholders who supported this proposal at a ratio of almost two and a half to one...
Frequently Asked Questions
Frequently Asked Questions
What is Acorda Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Acorda Therapeutics Inc shares?
plus_minus_icon
How can I buy Acorda Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Acorda Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Acorda Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Acorda Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Acorda Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Acorda Therapeutics Inc?
plus_minus_icon
What percentage is Acorda Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Acorda Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$13.05
$-0.45
(-3.33%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00